AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 173 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 0.72 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $5,221,000 | -32.9% | 101,100 | -43.7% | 0.02% | -36.8% |
Q4 2020 | $7,782,000 | -53.5% | 179,600 | -62.4% | 0.04% | -55.8% |
Q3 2020 | $16,725,000 | -6.2% | 477,852 | +43.4% | 0.09% | -25.9% |
Q2 2020 | $17,823,000 | +284.6% | 333,259 | +155.1% | 0.12% | +205.3% |
Q1 2020 | $4,634,000 | +1275.1% | 130,614 | +1834.2% | 0.04% | +1800.0% |
Q2 2019 | $337,000 | -95.6% | 6,753 | -94.0% | 0.00% | -94.1% |
Q1 2019 | $7,584,000 | +6.1% | 112,458 | -27.4% | 0.03% | -2.9% |
Q4 2018 | $7,147,000 | -47.3% | 155,000 | -11.8% | 0.04% | -37.5% |
Q3 2018 | $13,550,000 | +3.7% | 175,700 | +13.2% | 0.06% | +7.7% |
Q2 2018 | $13,072,000 | -60.6% | 155,200 | -61.8% | 0.05% | -62.6% |
Q1 2018 | $33,210,000 | +534.9% | 406,090 | +343.8% | 0.14% | +504.3% |
Q4 2017 | $5,231,000 | -39.5% | 91,500 | -29.4% | 0.02% | -41.0% |
Q3 2017 | $8,653,000 | -17.1% | 129,640 | -36.1% | 0.04% | -33.9% |
Q2 2017 | $10,444,000 | +186.1% | 203,000 | +224.8% | 0.06% | +195.0% |
Q1 2017 | $3,650,000 | -12.5% | 62,500 | -37.5% | 0.02% | -31.0% |
Q4 2016 | $4,173,000 | +97.6% | 100,000 | +116.9% | 0.03% | +107.1% |
Q2 2014 | $2,112,000 | – | 46,100 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Caligan Partners LP | 514,711 | $22,194,338 | 5.19% |
ACUTA CAPITAL PARTNERS, LLC | 78,700 | $3,393,544 | 2.86% |
Bellevue Group AG | 3,879,548 | $167,286,110 | 2.72% |
Parkman Healthcare Partners LLC | 446,416 | $19,249,458 | 2.58% |
Eagle Health Investments LP | 330,830 | $14,265,390 | 2.50% |
SECTOR GAMMA AS | 121,844 | $5,253,913 | 1.96% |
Frazier Life Sciences Management, L.P. | 871,974 | $37,599,519 | 1.76% |
BVF INC/IL | 1,190,107 | $51,317,414 | 1.44% |
Rock Springs Capital Management LP | 1,044,261 | $45,028,534 | 1.36% |
FARALLON CAPITAL MANAGEMENT LLC | 5,654,502 | $243,822,126 | 1.15% |